Invest in Progress 10-MINUTE TAKE: Enveda
5 snips
Apr 29, 2026 Viswa Colluru, founder and CEO of Enveda, builds AI tools to translate nature’s chemistry into drug leads. He discusses why natural molecules may beat lab-made compounds. He explains using mass spectrometry and LLM-like models to decode chemical fingerprints. He also covers partnerships with Sanofi and Microsoft and Enveda’s plan to scale toward blockbuster medicines.
AI Snips
Chapters
Transcript
Episode notes
Nature First Drug Discovery
- Enveda's core insight is that molecules sourced from nature are more likely to work in humans because they've been sampled by people for millennia.
- Viswa Colluru argues this lets the company find transformative drugs like aspirin or artemisinin in weeks rather than decades by focusing on nature's validated chemistry.
Personal Drive From Mother's Illness
- Viswa's motivation came from his mother's chronic myeloid leukemia and the family's struggle to pay for care in India.
- He learned entrepreneurship from his mother launching home businesses and committed aged 13 to prevent others hearing the same diagnosis.
Mass Spectra Decoded With LLM Grammar
- Enveda translates mass spectrometer 'fingerprints' into chemical structures using LLM-style context-aware models.
- They train on known and unknown molecules to reconstruct structures from fragmentation patterns, unlocking previously unidentifiable natural chemistry.